Novocure Shares Jump 26% on Trial Results for Pancreatic Cancer Therapy

Dow Jones

2024/12/02

By Denny Jacob

Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer.

Shares were trading around $25.22. The stock is up 34% on the year.

The oncology company and Zai Lab, a biopharmaceutical company, said a Phase 3 trial met its primary endpoint and demonstrated a statistically significant improvement in medical overall survival versus a control. The trial evaluated the use of tumor treating fields therapy concomitantly with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma.

Novocure said it plans to file for regulatory approval of the treatment and plans to submit the trial results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 02, 2024 07:41 ET (12:41 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2488675661"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488675661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488675661?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488675661","market":"sh","top_or_hot":-1,"title":"Novocure Shares Jump 26% on Trial Results for Pancreatic Cancer Therapy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer. \n</p>\n<p>\n  Shares were trading around $25.22. The stock is up 34% on the year. \n</p>\n<p>\n  The oncology company and Zai Lab, a biopharmaceutical company, said a Phase 3 trial met its primary endpoint and demonstrated a statistically significant improvement in medical overall survival versus a control. The trial evaluated the use of tumor treating fields therapy concomitantly with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma. \n</p>\n<p>\n  Novocure said it plans to file for regulatory approval of the treatment and plans to submit the trial results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 02, 2024 07:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Shares Jump 26% on Trial Results for Pancreatic Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Shares Jump 26% on Trial Results for Pancreatic Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-02 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer. \n</p>\n<p>\n  Shares were trading around $25.22. The stock is up 34% on the year. \n</p>\n<p>\n  The oncology company and Zai Lab, a biopharmaceutical company, said a Phase 3 trial met its primary endpoint and demonstrated a statistically significant improvement in medical overall survival versus a control. The trial evaluated the use of tumor treating fields therapy concomitantly with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma. \n</p>\n<p>\n  Novocure said it plans to file for regulatory approval of the treatment and plans to submit the trial results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 02, 2024 07:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488675661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488675661","pubTimestamp":1733143260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer.Shares were trading around $25.22. The stock is up 34% on the year.The oncology company and Zai Lab, a biopharmaceutical company, said a Phase 3 trial met its primary endpoint and demonstrated a statistically significant improvement in medical overall survival versus a control. The trial evaluated the use of tumor treating fields therapy concomitantly with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma.Novocure said it plans to file for regulatory approval of the treatment and plans to submit the trial results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","NVCR":"NovoCure Limited","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","BK4588":"碎股"},"translate_title":"Novocure股价因胰腺癌治疗试验结果上涨26%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer. \n\n\n  Shares were trading around $25.22. The stock is up 34% on the year. \n\n\n  The oncology company and Zai Lab, a biopharmaceutical company, said a Phase 3 trial met its primary endpoint and demonstrated a statistically significant improvement in medical overall survival versus a control. The trial evaluated the use of tumor treating fields therapy concomitantly with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma. \n\n\n  Novocure said it plans to file for regulatory approval of the treatment and plans to submit the trial results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2024 07:41 ET (12:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}